Method of treating intraoccular tissue pathologies with nerve growth factor
Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.
1. A method for treating glaucoma comprising: topically applying to an ocular surface of a human patient in need of such treatment an ophthalmic preparation comprising between about 10 μg/ml and about 500 μg/ml of nerve growth factor.
2. The method of claim 1 , wherein the ophthalmic preparation comprises nerve growth factor in a pharmaceutically acceptable ophthalmic carrier and is in a form selected from the group consisting of solutions, suspensions, ointments, gels and liniments.
3. The method of claim 2 , wherein the preparation is in the form of an ophthalmic solution.
4. The method of claim 2 , wherein the nerve growth factor is of human origin.
5. The method of claim 4 , wherein the nerve growth factor is a human recombinant nerve growth factor.
6. The method of claim 2 wherein the nerve growth factor is conjugated to a carrier molecule.
7. A method for treating optic neuritis comprising: topically applying to an ocular surface of a human patient in need of such treatment an ophthalmic preparation comprising between about 10 μg/ml and about 500 μg/ml of nerve growth factor.
8. The method of claim 7 , wherein the preparation comprises nerve growth factor in a pharmaceutically acceptable ophthalmic carrier and is in a form selected from the group consisting of solutions, suspensions, ointments, gels and liniments.
9. The method of claim 8 , wherein the preparation is in the form of an ophthalmic solution.
10. The method of claim 8 , wherein the nerve growth factor is of human origin.
11. The method of claim 10 wherein the nerve growth factor is a human recombinant nerve growth factor.
12. The method of claim 8 wherein the nerve growth factor is conjugated to a carrier molecule.
13. The method of claim 1 wherein the preparation is buffered to pH 4-8.
14. The method of claim 7 wherein the preparation is buffered to pH 4-8.